Literature DB >> 21840040

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.

Paul St Romain1, Rashna Madan, Ossama W Tawfik, Ivan Damjanov, Fang Fan.   

Abstract

Prior studies have suggested that the type of breast cancer influences the location of distant metastases ("organotropism") and that there may be discordance of estrogen receptor and human epidermal growth factor receptor 2 (Her2) expression between primaries and metastases. Our aims were to investigate the relationship between tumor type and metastatic site and to compare biomarker expression between primary and metastatic tumors. We retrospectively reviewed 102 biopsy-proven cases of breast cancer metastatic to distant sites from 2000 to 2010 and 34 corresponding primaries for histologic subtype, grade, lymphovascular invasion, lymph node metastasis, and expression of estrogen receptor and Her2. Most metastases were of ductal (88) and lobular (11) histologic types. Available data on primaries indicated that the majority were grade III with positive lymph node metastasis and lymphovascular invasion. Biomarkers on 73 metastases showed 37 estrogen receptor positive/Her2-, 6 estrogen receptor positive/Her2+, 8 estrogen receptor negative/Her2+, and 22 estrogen receptor negative/Her2-. The most common metastatic sites were the lung (26%), bone (32%), and liver (21%). We found no association between estrogen receptor/Her2 profile and metastatic site (P = .16). When compared with ductal carcinoma, lobular carcinoma showed a unique metastatic pattern to gastrointestinal tract/gynecologic sites (P = .014). Of 34 cases with paired prognostic markers for primary and metastatic sites, 7 (20%) demonstrated discordance in estrogen receptor-positive/Her2 profile between the primary and the metastasis. Because the estrogen receptor-positive/Her2 profile of metastatic breast cancer did not always match that of the primary tumor, it is important to repeat the prognostic markers of metastasis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840040     DOI: 10.1016/j.humpath.2011.05.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

Review 1.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

2.  Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.

Authors:  Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 3.  Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Authors:  Nadia Rucci; Patrizia Sanità; Simona Delle Monache; Edoardo Alesse; Adriano Angelucci
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 4.  [Secondary tumors of the gastrointestinal tract].

Authors:  C Langner
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

5.  Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.

Authors:  Jieqiong Liu; Heran Deng; Weijuan Jia; Yunjie Zeng; Nanyan Rao; Shunrong Li; Liang Jin; Jiannan Wu; Erwei Song; Fengxi Su
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

6.  Retrospective analysis of metastatic behaviour of breast cancer subtypes.

Authors:  C Dilara Savci-Heijink; Hans Halfwerk; Gerrit K J Hooijer; Hugo M Horlings; Jelle Wesseling; Marc J van de Vijver
Journal:  Breast Cancer Res Treat       Date:  2015-03-29       Impact factor: 4.872

7.  ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.

Authors:  Anna A Mourskaia; Eitan Amir; Zhifeng Dong; Kerstin Tiedemann; Sean Cory; Atilla Omeroglu; Nicholas Bertos; Véronique Ouellet; Mark Clemons; George L Scheffer; Morag Park; Michael Hallett; Svetlana V Komarova; Peter M Siegel
Journal:  Breast Cancer Res       Date:  2012-11-22       Impact factor: 6.466

8.  Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Authors:  Bahriye Aktas; Sabine Kasimir-Bauer; Volkmar Müller; Wolfgang Janni; Tanja Fehm; Diethelm Wallwiener; Klaus Pantel; Mitra Tewes
Journal:  BMC Cancer       Date:  2016-07-25       Impact factor: 4.430

9.  Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry.

Authors:  Stefan Stefanovic; Ralph Wirtz; Thomas M Deutsch; Andreas Hartkopf; Peter Sinn; Zsuzsanna Varga; Bettina Sobottka; Lakis Sotiris; Florin-Andrei Taran; Christoph Domschke; Andre Hennigs; Sara Y Brucker; Christof Sohn; Florian Schuetz; Andreas Schneeweiss; Markus Wallwiener
Journal:  Oncotarget       Date:  2017-05-19

10.  Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients.

Authors:  Yujie Lu; Yiwei Tong; Xiaosong Chen; Kunwei Shen
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.